Saturday 17 October 2026
Export TXMD’s income statement to Excel — free account
TherapeuticsMD, Inc.
TXMD Healthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024. In the quarter to June 2026, revenue fell 8.72%, EPS fell 80.0% and free cash flow grew 104.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.90
0.03
−1.55%
Follow TXMD
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 5 | 1 | 4 | 2 | 2 | 7 | 3 | 6 | 6 |
Altman Z-Score |
41.36 | 51.52 | (0.06) | (3.26) | (8.13) | (10.84) | (13.06) | (30.18) | (34.06) | (34.36) |
P/S ratio |
60.48 | 76.81 | 53.25 | 12.01 | 5.14 | 55.69 | 0.81 | 18.68 | 5.63 | 6.24 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.28 | 0.00 | 12.49 | 9.07 |
Altman Z″-Score (non-manufacturers) |
3.32 | 3.58 | (6.71) | (8.47) | (19.46) | (28.92) | (32.48) | (69.86) | (77.28) | (78.93) |
P/Operating CF |
(74.96) | (61.94) | (30.46) | (11.73) | (10.99) | 2.98 | 1.87 | (4.90) | 583.38 | 50.29 |
Beneish M-Score |
(2.96) | (2.51) | (1.67) | (0.87) | (2.86) | 19.79 | — | — | (2.58) | (2.54) |
P/B ratio |
9.18 | 9.92 | 8.79 | 64.79 | 0.00 | 0.00 | 1.61 | 0.83 | 0.36 | 0.70 |
Price to Tangible BV |
9.36 | 10.16 | 11.68 | 0.00 | 0.00 | 0.00 | 2.00 | 1.05 | 0.43 | 0.82 |
EV/Sales |
53.68 | 69.23 | 47.77 | 12.72 | 7.60 | 170.38 | 3.89 | 219.16 | 153.43 | 91.57 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 114.28 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(15.03) | (15.25) | (7.20) | (3.81) | (3.09) | (7.95) | 29.11 | (12.36) | 230.94 | 112.76 |
EV/FCF |
(14.76) | (15.09) | (6.00) | (3.33) | (3.06) | (7.64) | 30.33 | (12.16) | 340.30 | 133.16 |
Quick Ratio |
9.08 | 9.87 | 4.20 | 3.49 | 1.91 | 0.40 | 1.05 | 1.08 | 1.67 | 2.30 |
Current Ratio |
9.30 | 10.48 | 4.55 | 3.93 | 2.17 | 0.47 | 1.18 | 1.72 | 2.37 | 3.02 |
Net Debt/EBITDA |
1.46 | 1.64 | 0.68 | (0.24) | (1.05) | (1.56) | (20.69) | 0.57 | 1.05 | 2.34 |
Debt/Assets |
0.00% | 0.00% | 34.62% | 73.74% | 132.12% | 111.09% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.75 | 21.32 | (1.94) | (2.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.18 | 0.12 | 0.09 | 0.21 | 0.29 | 0.01 | 0.54 | 0.02 | 0.04 | 0.08 |
Operating CF/Net income |
0.77 | 0.99 | 0.81 | 0.94 | 0.87 | 0.32 | 0.08 | 2.25 | (0.54) | (4.31) |
Capex/Depreciation |
(9.37) | (3.88) | (37.83) | (17.16) | (0.39) | (3.02) | (0.30) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(8,356.81) | (10,081.65) | (27.84) | (8.70) | (5.44) | (2.42) | — | — | — | — |
| (94.33%) | (59.77%) | (116.62%) | (330.09%) | 319.73% | 158.45% | (383.04%) | (31.90%) | (7.70%) | (2.10%) | |
| (83.14%) | (53.85%) | (74.67%) | (73.71%) | (82.00%) | (98.22%) | 86.17% | (15.37%) | (5.31%) | (1.49%) | |
ROIC |
0.00% | (1,749.59%) | (875.89%) | (212.33%) | (274.11%) | (167.23%) | 0.00% | (21.34%) | (17.12%) | (14.15%) |
Return on Tangible Assets |
(71.93%) | (60.73%) | (90.73%) | (111.54%) | (258.09%) | 130.03% | 1,303.81% | (207.97%) | (30.75%) | (5.89%) |
Average Days of Receivables |
84.87 | 94.17 | 250.83 | 179.36 | 182.20 | 5,131.85 | 0.00 | 866.24 | 738.29 | 425.75 |
Research and Development Expense of Revenue |
278.68% | 201.77% | 169.56% | 39.87% | 16.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
265.28% | 343.93% | 720.45% | 351.93% | 299.06% | 3,138.28% | 81.06% | 683.79% | 346.17% | 226.74% |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.11 | 0.17 | 0.23 | 0.04 | 0.08 | 0.14 | 0.11 | 0.10 |
Share Based Compensation of Revenue |
89.95% | 41.06% | 53.80% | 21.52% | 16.46% | 704.43% | 16.54% | 97.62% | 14.99% | 2.48% |
Graham Net Nets |
0.11 | 0.10 | 0.08 | (0.08) | (0.53) | (1.00) | 0.00 | (0.09) | 0.08 | 0.19 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 130.21 | 75.43 | 32.96 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(7.87%) | (6.06%) | (15.49%) | (29.34%) | (55.37%) | (119.44%) | 198.43% | (42.62%) | (20.71%) | (3.28%) |
Free Cash Flow Yield |
(6.01%) | (5.97%) | (14.95%) | (31.80%) | (48.29%) | (40.03%) | 15.92% | (96.42%) | 8.01% | 11.02% |
Revenue per Share |
4.94 | 4.08 | 3.58 | 10.08 | 11.77 | 0.32 | 7.75 | 0.12 | 0.15 | 0.26 |
Operating CF per Share |
(17.63) | (18.53) | (23.73) | (33.63) | (28.93) | (6.93) | 1.04 | (2.21) | 0.10 | 0.21 |
Capex per Share |
(0.32) | (0.20) | (4.74) | (4.85) | (0.29) | (0.28) | (0.04) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(17.95) | (18.73) | (28.47) | (38.48) | (29.22) | (7.21) | 1.00 | (2.21) | 0.10 | 0.21 |
Cash per Share |
33.54 | 30.93 | 35.91 | 32.64 | 14.60 | 8.15 | 5.46 | 0.41 | 0.44 | 0.65 |
Shareholders Equity per Share |
32.51 | 31.60 | 21.67 | 1.87 | (22.49) | (11.76) | 3.89 | 2.81 | 2.37 | 2.32 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
32.51 | 31.60 | 21.67 | 1.87 | (22.49) | (11.76) | 3.89 | 2.81 | 2.37 | 2.32 |
Free Cash Flow |
(70.38) | (76.98) | (128.13) | (189.61) | (161.07) | (57.36) | 9.00 | (23.08) | 1.17 | 2.45 |
Working Capital |
124.43 | 126.23 | 145.70 | 155.41 | 69.17 | (133.42) | 8.51 | 4.94 | 7.09 | 9.66 |
Capital Expenditures |
(1.24) | (0.83) | (21.32) | (23.89) | (1.60) | (2.22) | (0.35) | — | — | — |
Net Current Asset Value |
124.43 | 126.23 | 72.32 | (48.37) | (177.21) | (143.62) | 0.04 | (2.23) | 0.81 | 3.67 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 228.76 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.06 | 0.05 | 1.32 | 0.48 | 0.02 | 0.86 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.38 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.26 | 0.49 | 1.19 | 0.56 | 2.09 | 0.89 | 15.29 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(27.17%) | (29.95%) | (38.53%) | (51.78%) | (82.00%) | (35.95%) | 10.66% | (68.66%) | 3.61% | 7.14% |
Accounts Receivable Turnover |
5.13 | 3.80 | 2.09 | 2.80 | 2.29 | 0.08 | 0.00 | 0.07 | 0.53 | 0.85 |
Accounts Payable Turnover |
0.80 | 0.46 | 0.20 | 0.30 | 0.79 | 0.11 | 0.50 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
4.74 | 2.06 | 1.15 | 0.84 | 1.61 | 0.18 | 0.00 | — | — | — |
Average Days of Payables |
641.67 | 567.19 | 3,032.29 | 1,105.15 | 481.37 | 878.13 | 564.87 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
93.86 | 205.61 | 435.66 | 683.37 | 182.63 | 0.00 | 0.00 | — | — | — |
Average Receivables |
3.78 | 4.41 | 7.70 | 17.73 | 28.39 | 34.28 | — | 19.63 | 3.33 | 3.54 |
Average Payables |
5.24 | 5.73 | 13.42 | 20.96 | 20.12 | 12.22 | 2.77 | 1.09 | 0.14 | 0.32 |
Average Inventory |
0.88 | 1.28 | 2.38 | 7.56 | 9.93 | 7.81 | — | — | — | — |
Average Assets |
108.10 | 142.85 | 177.61 | 238.98 | 223.80 | 175.54 | 129.97 | 66.88 | 41.07 | 38.24 |
Average Common Equity |
95.28 | 128.70 | 113.72 | 53.36 | (57.40) | (108.81) | (29.24) | 32.22 | 28.33 | 27.12 |
Columns are period end dates